Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care
Quest Diagnostics (NYSE: DGX) has completed its acquisition of select clinical testing assets from Spectra Laboratories, owned by Fresenius Medical Care. The deal positions Quest to provide dialysis-related clinical testing to independent dialysis clinics previously served by Spectra.
Under a separate laboratory services agreement, Quest will begin providing comprehensive dialysis-related laboratory services for Fresenius Medical Care's U.S. dialysis centers, serving approximately 200,000 patients annually. The service transition will start this month and is expected to complete by early 2026.
The strategic acquisition will leverage Quest's laboratory network to reduce transportation time and expedite results reporting. Quest plans to optimize capital returns by utilizing its facilities during lower-volume daytime hours.
Quest Diagnostics (NYSE: DGX) ha completato l'acquisizione di specifici asset per test clinici da Spectra Laboratories, societ脿 controllata da Fresenius Medical Care. Questa operazione consente a Quest di offrire test clinici correlati alla dialisi alle cliniche indipendenti di dialisi precedentemente servite da Spectra.
In base a un accordo separato sui servizi di laboratorio, Quest inizier脿 a fornire servizi di laboratorio completi legati alla dialisi per i centri di dialisi statunitensi di Fresenius Medical Care, assistendo circa 200.000 pazienti all'anno. La transizione del servizio inizier脿 questo mese e dovrebbe concludersi entro i primi mesi del 2026.
Questa acquisizione strategica sfrutter脿 la rete di laboratori di Quest per ridurre i tempi di trasporto e accelerare la comunicazione dei risultati. Quest prevede di ottimizzare i ritorni sul capitale utilizzando le sue strutture durante le ore diurne a basso volume.
Quest Diagnostics (NYSE: DGX) ha completado la adquisici贸n de ciertos activos de pruebas cl铆nicas de Spectra Laboratories, propiedad de Fresenius Medical Care. Este acuerdo posiciona a Quest para ofrecer pruebas cl铆nicas relacionadas con la di谩lisis a cl铆nicas de di谩lisis independientes que anteriormente eran atendidas por Spectra.
Bajo un acuerdo separado de servicios de laboratorio, Quest comenzar谩 a proporcionar servicios integrales de laboratorio relacionados con la di谩lisis para los centros de di谩lisis de Fresenius Medical Care en EE. UU., atendiendo aproximadamente a 200,000 pacientes anualmente. La transici贸n del servicio comenzar谩 este mes y se espera que finalice a principios de 2026.
La adquisici贸n estrat茅gica aprovechar谩 la red de laboratorios de Quest para reducir el tiempo de transporte y acelerar la entrega de resultados. Quest planea optimizar el retorno de capital utilizando sus instalaciones durante las horas diurnas de menor volumen.
韤橃姢韸� 雼れ澊鞎勱犯雲胳姢韹膘姢(NYSE: DGX)電� 頂勲爤鞝滊媹鞖办姢 氅旊敂旎� 旒�鞏搓皜 靻岇湢頃� 鞀ろ帣韸鸽澕 霝橂矂霟啝毽姢鞚� 鞚茧秬 鞛勳儊 瓴�靷� 鞛愳偘 鞚胳垬毳� 鞕勲頄堨姷雼堧嫟. 鞚措矆 瓯半灅搿� 韤橃姢韸鸽姅 鞚挫爠鞐� 鞀ろ帣韸鸽澕臧� 靹滊箘鞀るゼ 鞝滉车頃橂崢 霃呺 韴劃 韥措Μ雼夓棎 韴劃 甏�霠� 鞛勳儊 瓴�靷ゼ 鞝滉车頃� 靾� 鞛堦矊 霅橃棃鞀惦媹雼�.
氤勲弰鞚� 鞁ろ棙鞁� 靹滊箘鞀� 瓿勳暯鞐� 霐半澕 韤橃姢韸鸽姅 頂勲爤鞝滊媹鞖办姢 氅旊敂旎� 旒�鞏� 氙戈淡 雮� 韴劃 靹柬劙鞐� 雽�頃� 韽磩鞝侅澑 韴劃 甏�霠� 鞁ろ棙鞁� 靹滊箘鞀るゼ 鞝滉车頃� 鞓堨爼鞚措┌, 鞐瓣皠 鞎� 200,000氇呾潣 頇橃瀽毳� 歆�鞗愴暕雼堧嫟. 靹滊箘鞀� 鞝勴櫂鞚� 鞚措矆 雼秬韯� 鞁滌瀾霅橃柎 2026雲� 齑堦箤歆� 鞕勲霅� 鞓堨爼鞛呺媹雼�.
鞚措矆 鞝勲灥鞝� 鞚胳垬電� 韤橃姢韸胳潣 鞁ろ棙鞁� 雱ろ姼鞗岉伂毳� 頇滌毄頃� 鞖挫啞 鞁滉皠鞚� 雼稌頃橁碃 瓴瓣臣 氤搓碃毳� 鞁犾啀頃橁矊 頃� 靾� 鞛堧弰搿� 頃╇媹雼�. 韤橃姢韸鸽姅 雮� 鞁滉皠雽� 雮潃 瓴�靷焿鞚� 頇滌毄頃� 鞛愲掣 靾橃澋鞚� 斓滌爜頇旐暊 瓿勴殟鞛呺媹雼�.
Quest Diagnostics (NYSE : DGX) a finalis茅 l'acquisition de certains actifs de tests cliniques de Spectra Laboratories, d茅tenue par Fresenius Medical Care. Cette op茅ration permet 脿 Quest de fournir des tests cliniques li茅s 脿 la dialyse aux cliniques de dialyse ind茅pendantes pr茅c茅demment desservies par Spectra.
Dans le cadre d'un accord distinct de services de laboratoire, Quest commencera 脿 fournir des services de laboratoire complets li茅s 脿 la dialyse pour les centres de dialyse am茅ricains de Fresenius Medical Care, desservant environ 200 000 patients par an. La transition des services d茅butera ce mois-ci et devrait 锚tre achev茅e d茅but 2026.
Cette acquisition strat茅gique tirera parti du r茅seau de laboratoires de Quest pour r茅duire les d茅lais de transport et acc茅l茅rer la communication des r茅sultats. Quest pr茅voit d'optimiser le rendement du capital en utilisant ses installations pendant les heures de faible affluence en journ茅e.
Quest Diagnostics (NYSE: DGX) hat den Erwerb ausgew盲hlter klinischer Testanlagen von Spectra Laboratories, einem Unternehmen von Fresenius Medical Care, abgeschlossen. Mit diesem Deal positioniert sich Quest, um unabh盲ngigen Dialysekliniken, die zuvor von Spectra bedient wurden, dialysebezogene klinische Tests anzubieten.
Im Rahmen einer separaten Laborvereinbarung wird Quest umfassende dialysebezogene Laborleistungen f眉r die Dialysezentren von Fresenius Medical Care in den USA erbringen und dabei etwa 200.000 Patienten j盲hrlich betreuen. Die 脺bergabe der Dienstleistungen beginnt noch in diesem Monat und soll Anfang 2026 abgeschlossen sein.
Die strategische 脺bernahme nutzt das Labornetzwerk von Quest, um Transportzeiten zu verk眉rzen und die Ergebnisberichterstattung zu beschleunigen. Quest plant, die Kapitalrendite zu optimieren, indem die Einrichtungen w盲hrend der weniger ausgelasteten Tageszeiten genutzt werden.
- Expansion into dialysis testing market serving 200,000 patients annually
- Strategic optimization of laboratory network utilization during low-volume hours
- Reduced transportation time and faster results reporting through multiple U.S. laboratories
- Entry into growing market with 800,000+ dialysis patients in the U.S.
- Additional revenue stream from water testing assets acquisition expected by end of 2025
- Extended transition period until early 2026 may impact immediate revenue recognition
- Capital investment required for laboratory network optimization
- Integration costs and operational challenges during transition period
Insights
Quest's acquisition of Spectra Labs assets strategically expands its dialysis testing market share while optimizing laboratory capacity utilization.
Quest Diagnostics has completed a strategic acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories, positioning the company to serve independent dialysis clinics previously under Spectra's umbrella. This move represents a significant expansion in the renal testing market for Quest.
The deal includes two key components: the completed acquisition of clinical testing assets and a pending acquisition of water testing assets expected by year-end. Notably, Quest has also secured a comprehensive laboratory services agreement with Fresenius Medical Care to provide testing for their dialysis centers serving approximately
This acquisition offers multiple strategic advantages for Quest. First, it provides immediate entry into a substantial patient population, as chronic kidney disease affects
Perhaps most importantly, Quest has identified a clever operational efficiency by noting they'll perform this testing during "lower-volume daytime hours" - effectively utilizing excess capacity in their existing laboratory network. This approach optimizes their return on capital by filling otherwise underutilized capacity without requiring significant additional infrastructure investment.
With over 800,000 Americans receiving dialysis and requiring regular laboratory monitoring, this acquisition secures Quest a significant position in a stable, recurring revenue stream with built-in growth potential as the kidney disease population continues expanding.
In addition, under a separate, laboratory services agreement, Quest later this month will begin to provide comprehensive dialysis-related laboratory services for dialysis centers operated by Fresenius Medical Care in
The arrangement will allow providers and patients at dialysis clinics to benefit from Quest's clinical leadership and diagnostic innovation in chronic kidney disease services. Multiple Quest laboratories across the
聽affects about 35.5 million people, or
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in
View original content to download multimedia:
SOURCE Quest Diagnostics
FAQ
What assets did Quest Diagnostics (DGX) acquire from Fresenius Medical Care?
How many patients will Quest Diagnostics serve through the Fresenius Medical Care agreement?
When will Quest Diagnostics complete the transition of Fresenius Medical Care's laboratory services?
What is the market size for dialysis services in the United States?
How will Quest Diagnostics optimize its laboratory operations through this acquisition?
